Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orphan drug "windfall profit" tax bill

Executive Summary

Rep. Stark (D-Calif.) introduces bill (HR 1588) April 1 that would impose a 75% tax on any gross revenues from orphan drugs over 125% the cost of production and marketing of the drug for the year. Such revenues would not be taxed until development costs were recovered. A similar bill was introduced by Stark last October.

Rep. Stark (D-Calif.) introduces bill (HR 1588) April 1 that would impose a 75% tax on any gross revenues from orphan drugs over 125% the cost of production and marketing of the drug for the year. Such revenues would not be taxed until development costs were recovered. A similar bill was introduced by Stark last October.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel